» Articles » PMID: 23620000

Comparable Long-term Outcomes After Reduced-intensity Conditioning Versus Myeloablative Conditioning Allogeneic Stem Cell Transplantation for Adult High-risk Acute Lymphoblastic Leukemia in Complete Remission

Overview
Journal Am J Hematol
Specialty Hematology
Date 2013 Apr 27
PMID 23620000
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The role of reduced-intensity conditioning (RIC) in adult acute lymphoblastic leukemia (ALL) remains unclear because of the small sample size, short follow-up duration, various regimens for conditioning and graft-versus-host disease (GVHD) prophylaxis, and the heterogeneity of selection criteria for transplantation. We compared long-term outcomes of 60 consecutive RIC transplants (fludarabine plus melphalan) with 120 myeloablative conditioning (MAC) transplants (total body irradiation plus cyclophosphamide) for adult high-risk ALL in first or second complete remission. All transplants received a uniform strategy of pretransplant chemotherapy and GVHD prophylaxis. Compared to MAC transplants, RIC transplants had older age (46 years vs. 33 years, P < 0.001) and higher proportions of transplantation using peripheral blood (93.3% vs. 13.3%; P < 0.001) but otherwise showed similar characteristics. After a median follow-up of 67 months, RIC transplants showed comparable nonrelapse mortality (21.2% vs. 24.3%) and disease-free survival (50.8% vs. 54.9%) to MAC transplants, although relapse risk was higher (34.2% vs. 26.4%; HR, 2.07; P = 0.019) in multivariate analysis. Other independent factors associated with better outcomes were the presence of chronic GVHD and transplantation in first complete remission. Interestingly, the negative impact of RIC on relapse risk was seen only for Philadelphia-positive ALL transplants (32.7% vs. 19.6%; HR, 3.46; P = 0.020), while no difference was found between RIC and MAC for Philadelphia-negative ALL transplants (35.0% vs. 32.1%; HR, 1.39; P = 0.429). RIC can be considered as a reasonable choice for providing a sufficient long-term graft-versus-leukemia effect for adult high-risk ALL patients ineligible for MAC.

Citing Articles

Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the gene: a case report and literature review.

Jin X, Liu Z, Wu Y, Ji J Front Immunol. 2025; 15:1475974.

PMID: 39877348 PMC: 11772267. DOI: 10.3389/fimmu.2024.1475974.


Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia.

Larue M, Labopin M, Schroeder T, Huang X, Blau I, Schetelig J Hemasphere. 2024; 8(10):e70026.

PMID: 39440198 PMC: 11494155. DOI: 10.1002/hem3.70026.


Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia.

Ahn J, Yoon J, Kwag D, Min G, Park S, Park S Bone Marrow Transplant. 2024; 59(10):1413-1422.

PMID: 38997400 DOI: 10.1038/s41409-024-02363-7.


Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy.

Yoon J, Lee S Korean J Intern Med. 2024; 39(1):34-56.

PMID: 38225824 PMC: 10790045. DOI: 10.3904/kjim.2023.407.


Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.

Hirschbuhl K, Labopin M, Polge E, Blaise D, Bourhis J, Socie G Bone Marrow Transplant. 2023; 58(8):874-880.

PMID: 37147469 PMC: 10400409. DOI: 10.1038/s41409-023-01966-w.